Epigral Ltd

Epigral Ltd

₹ 1,216 -2.57%
15 May - close price
About

Epigral Limited, formerly known as Meghmani Finechem Ltd, incorporated in 2007, is a leading integrated manufacturer of chemicals in India. Epigral’s Dahej facility is a backward and forward integrated and automated complex with a well-planned infrastructure.

In India, Epigral is the first to set up an Epichlorohydrin plant and largest capacity plant of CPVC Resin. Epigral is also a leading manufacturer of Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, Chlorine and Hydrogen.

Key Points

Product Segments
a. Derivatives & Speciality Chemicals (56% in H1 FY25 vs 25% in FY22): [1] [2] The company is the 5th largest producer of Chloromethanes (CMS) in India, its CMS portfolio includes MDC, Chloroform and CTC. It is also 3rd largest producer of Hydrogen Peroxide in India. [3] It also produces specialty chemicals like CPVC Resin, CPVC compound, Epichlorohydrin, Chlorotoluenes Value Chain, etc. [4]

  • Market Cap 5,261 Cr.
  • Current Price 1,216
  • High / Low 2,114 / 806
  • Stock P/E 15.8
  • Book Value 515
  • Dividend Yield 0.41 %
  • ROCE 15.6 %
  • ROE 16.2 %
  • Face Value 10.0

Pros

  • Company's median sales growth is 25.5% of last 10 years

Cons

  • Tax rate seems low
  • Debtor days have increased from 42.4 to 60.2 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
562 455 478 472 525 651 626 645 628 607 587 597 736
407 360 370 349 369 475 448 463 454 443 455 494 568
Operating Profit 155 95 108 123 155 176 178 183 173 163 132 103 169
OPM % 28% 21% 23% 26% 30% 27% 28% 28% 28% 27% 23% 17% 23%
5 2 1 2 2 2 6 4 3 8 2 6 -1
Interest 19 18 21 20 14 14 27 -0 12 23 22 11 16
Depreciation 30 31 32 31 30 33 32 33 34 42 42 43 42
Profit before tax 110 48 56 74 113 131 124 154 131 107 70 55 111
Tax % 30% 33% 32% 34% 32% 34% 35% 33% 34% -50% 26% 28% 26%
77 32 38 49 77 86 81 104 87 160 52 39 82
EPS in Rs 18.48 7.62 9.18 11.87 18.45 20.70 19.38 24.00 20.08 37.18 11.94 9.07 18.99
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
394 392 598 710 611 829 1,551 2,188 1,929 2,550 2,527
245 248 346 405 416 567 1,041 1,499 1,448 1,839 1,960
Operating Profit 149 144 252 306 194 261 510 689 481 711 567
OPM % 38% 37% 42% 43% 32% 32% 33% 31% 25% 28% 22%
2 1 8 16 2 2 4 8 6 15 15
Interest 19 14 9 25 11 29 44 66 73 53 72
Depreciation 44 55 55 54 44 74 86 109 124 133 168
Profit before tax 88 75 195 242 141 161 383 523 291 540 342
Tax % 23% 11% 20% 25% 21% 37% 34% 32% 33% 34% 3%
67 67 155 183 112 101 253 353 196 357 333
EPS in Rs 9.49 9.40 21.97 44.38 27.19 24.48 60.84 85.04 47.12 82.68 77.19
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% 6% 11% 7% 6%
Compounded Sales Growth
10 Years: 20%
5 Years: 25%
3 Years: 5%
TTM: -1%
Compounded Profit Growth
10 Years: 17%
5 Years: 27%
3 Years: -2%
TTM: -5%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 8%
1 Year: -34%
Return on Equity
10 Years: 26%
5 Years: 24%
3 Years: 18%
Last Year: 16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 71 71 71 41 42 42 42 42 42 43 43
Reserves 224 291 447 241 331 432 684 1,028 1,213 1,860 2,178
190 123 74 601 737 753 993 879 964 593 572
55 42 79 162 164 223 405 484 576 655 712
Total Liabilities 540 527 671 1,044 1,273 1,449 2,124 2,432 2,794 3,151 3,505
364 398 347 295 440 1,102 1,068 1,804 1,767 2,238 2,117
CWIP 69 3 79 468 691 126 589 158 483 64 451
Investments -0 29 71 -0 -0 0 0 21 21 97 23
106 98 173 281 142 221 467 449 524 752 915
Total Assets 540 527 671 1,044 1,273 1,449 2,124 2,432 2,794 3,151 3,505

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
165 229 284 626 398 441 436
-363 -197 -455 -437 -401 -262 -355
69 -32 195 -200 -8 -164 -94
Net Cash Flow -129 1 24 -11 -11 15 -14
Free Cash Flow -205 32 -172 210 -1 254 50
CFO/OP 99% 99% 68% 106% 93% 78% 90%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 43 41 47 40 46 52 60 28 34 33 60
Inventory Days 75 59 45 58 64 51 74 69 90 105 89
Days Payable 31 37 51 52 62 69 42 36 63 50 66
Cash Conversion Cycle 86 63 42 46 48 34 92 61 61 88 83
Working Capital Days 43 40 19 -27 -76 -92 -26 -41 -54 26 16
ROCE % 18% 37% 36% 15% 16% 29% 32% 17% 25% 16%

Insights

In beta
Mar 2010 Mar 2015 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Dec 2025
Installed Capacity - Caustic Soda
KTPA

Log in to view insights

Please log in to see hidden values.

Login
Production Volume - Chloromethanes
MT
Installed Capacity - CPVC Resin
KTPA
Installed Capacity - Epichlorohydrin (ECH)
KTPA
Overall Plant Utilization
%
Chlorine Integration level
%
Electrochemical Unit (ECU) Realization
INR/MT

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
71.37% 71.38% 71.38% 71.49% 71.58% 71.58% 68.94% 68.95% 68.83% 68.83% 68.83% 68.83%
1.16% 1.14% 1.17% 1.36% 1.46% 2.10% 3.01% 3.01% 3.06% 2.71% 2.36% 1.54%
0.04% 0.04% 0.05% 0.02% 0.18% 1.17% 4.31% 4.66% 4.78% 4.93% 5.13% 4.90%
0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02%
27.39% 27.40% 27.37% 27.10% 26.75% 25.12% 23.71% 23.34% 23.30% 23.52% 23.67% 24.71%
No. of Shareholders 95,83395,74292,95988,87085,76183,17681,69780,87879,95178,60577,56277,583

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls